Retatrutide is a new triple-receptor agonist peptide originated from the GLP-1-based dual agonist Tirzepatide. It selectively targets three key metabolic receptors: the glucagon receptor (ГКГР), the glucose-dependent insulinotropic polypeptide receptor (GIPR), и рецептор глюкагоноподобного пептида-1 (ГЛП-1Р). This new peptide drug shows strong potential in treating obesity-related metabolic disorders and type 2 diabetes due to its unique structure.
Более того, Scientists developed Retatrutide peptide on an optimized GLP-1 analog scaffold and it consists of 39 аминокислоты. Its sequence incorporates three non-natural amino acids to enhance resistance to degradation by dipeptidyl peptidase-4 (DPP-4). Более того, the introduction of AIB (2-Aminoisobutyric acid) significantly improves both biological activity and pharmacokinetics.
Кроме того, the attachment of a C20 fatty diacid chain a лизин residue extends its период полураспада and improves its pharmacological profile. Вместе, these advanced features support once-weekly subcutaneous dosing.
Последовательность
Tyr-{Аиб}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Лис}-Ala-Gln-{Аиб}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Номер CAS
2381089-83-2
Молекулярная формула
C221H342N46O68
Молекулярный вес
4731.33 г/моль
Research Of Retatrutide Benefits:
1. Suppresses Appetite, Delays Gastric Emptying, and Stimulates Insulin
1)Mechanism of Action in Appetite Control:
In an animal study, researchers fasted male obese mice для 16 hours and treated them with long-acting glucagon receptor agonists, Ретатрутид, galectin peptides, and other GLP-1 analogs for weight management. The study evaluated gastric emptying (GE) delay, body weight, and food intake.
2)Glucose-Dependent Gastric Emptying Delay:
Примечательно, Retatrutide delayed GE in a glucose-dependent manner. В частности, the group receiving 10 nmol/L Retatrutide showed the highest reduction in body weight and the largest decrease in food consumption.
3)Central Nervous System Effects:
Similarly to other GLP-1 receptor agonist, Retatrutide acts directly on the central nervous system, enhancing satiety and slowing gastric emptying. Как результат, it supports effective obesity treatment.
4)Clinical Trial Weight Loss Results:
Например, a Phase 2 clinical trial reported significant weight loss in overweight and obese adults: 17.5% в 24 weeks and 24.4% в 48 недели.
2. Treats Type 2 Диабет
- A Phase 1b multiple ascending-dose study involved type 2 diabetes patients receiving weekly doses of Retatrutide or other glucose-lowering drugs, with a control group receiving no treatment.
- Remarkably, Retatrutide achieved 100% of the weight loss target, compared to only 2.1% in the control group. В отличие, no other diabetes drug reached 50% эффективность.
- These findings clearly demonstrate Retatrutide’s superior effectiveness in managing type 2 диабет. Однако, the most common side effects were gastrointestinal.
- В то же время, in obese adults, Retatrutide treatment also led to significant weight loss over 48 недели.
3. Promotes Energy Expenditure
- As a triple agonist, Retatrutide activates the glucagon receptor similarly to glucagon. Конкретно, it directly stimulates thermogenesis and fat breakdown.
- It is important to note that glucagon receptors are present in the liver and жировая ткань. By activating these receptors, Retatrutide increases energy expenditure and heat production in the liver.
- Следовательно, it boosts metabolic rate and promotes fat oxidation.
4. Reduces Inflammation and Treats Fatty Liver Disease
1)Anti-Inflammatory Benefits:
Retatrutide offers multi-faceted anti-inflammatory benefits. Например, studies show it improves glucose tolerance, reduces body weight and fat mass, and enhances lipid profiles.
2)Reversal of Steatohepatitis in Mice:
Кроме того, it reverses steatohepatitis in female mice, supporting resolution of fatty liver disease by reducing hepatic steatosis. In one study, mice that researchers fed a high-fat, high-sugar diet for 38 weeks received subcutaneous Retatrutide, and researchers fasted them for 4 часы.
Впоследствии, histological analysis showed over 80% had definite steatohepatitis. Importantly, Retatrutide improved the condition dose-dependently, with some females showing complete reversal.
3)Histological Analysis Results:
In another human trial, researchers treated 98 participants with ≥10% liver fat content. После 48 weeks of Retatrutide treatment, liver fat decreased by 51.3% (1 мг), 59% (4 мг), и 86% (12 мг), по сравнению с 4.6% in the control group.
В конечном счете, all treated patients achieved normal liver fat levels.
сертификат подлинности
ВЭЖХ
РС
Примечания к цитированию статей/литературных источников





